UK samples collected before February 2020*

Review existing biological risk assessment

Source disease status & tissue association, also epidemiological and geographical factors

Open further guidance

Is the sample likely to be contaminated with HG3 pathogens - (e.g. BBVs, Mycobacterium spp. etc)?

Open further guidance

CL-2 with any additional exposure controls. Assess risk of inadvertent pathogen propagation

Inadvertent propagation of HG3 pathogens increases risk

Open further guidance

All respiratory sample processing

Other samples control aerosol and droplet generating processes such as:

- Pipetting
- Vortexing & mixing
- Centrifugation

Use sealed buckets. Loading and unloading inside MSC or risk assess

CL-3

False

Known / presumed positive, consider:

- Diagnosed / tested COVID-19 patients
- Symptomatic individuals
- Asymptomatic in isolation
- Higher risk groups (e.g. HCW etc)

No deliberate or inadvertent virus culture and procedures being used align with the PHE guidance for diagnostic work at CL-2

Open PHE guidance

CL-2

True

Validated virus inactivation

All activities require Advisory Group/GMSC review and approval. HSE clearance may also be needed.

Work may require a combination of containment levels

Complex risk assessments should include a flow chart showing how different samples will be processed

* assess appropriate date if samples are from another country